Roche's hemophilia treatment well on the way to triple blockbuster status
The acceleration in sales of Roche's Hemlibra, which competes with Novo Nordisk in an increasingly hot market, has continued. Sales for the first half year totaled more than USD 1.5bn.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
At the six-month mark of 2021, total sales at Roche can be seen to have acellerated after a slightly slow start, reaching CHF 14.8bn (USD 16bn) for Q2 and CHF 30.71bn (USD 33.46bn) for the first half of the year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Roche reports slightly better sales than predicted in Q1
For subscribers
Roche publishes new sclerosis data to keep Novartis at bay
For subscribers
.jpg&w=384&q=75)
